Second Clinton Presidency Could Spur Adoption Of Price Controls, Bio Exec Warns
This article was originally published in The Pink Sheet Daily
A Democratic president in 2008 will likely weigh on pricing, Biotechnology Industry Organization exec says.
You may also be interested in...
In a letter to President Bush, Sen. Kennedy (D-Mass.) and Rep. Waxman (D-Calif.) say that giving HHS the authority to negotiate pharmaceutical prices would save $190 bil. over the next decade, with no reduction in benefits.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products